Racial and clinical determinants of response in 2304 large B-cell lymphomas treated with CD19 CAR T in clinical trials.

Soon Jye Kho¹, Sheila Diamond¹, Penelope Lafeuille¹, Jonathan H Schatz², Francesco Maura³, Jacob Aptekar¹, Frederick L Locke⁴

¹Medidata, New York, NY.

²Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.

³Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.

PubMed PMC DOI PDF

Abstract

Chimeric antigen receptor T-cell (CAR T) therapy has advanced treatment for B-cell lymphoma (BCL), but >50% of patients relapse. Predicting clinical outcomes based on features at CAR T infusion remains unclear, and most trials lack racial diversity, limiting understanding of its impact on outcomes. To address these challenges, we pooled data from 9 CAR T clinical trials, consisting of 2304 patient…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.